Listing 1 - 10 of 45 | << page >> |
Sort by
|
Choose an application
psychology --- behavioural sciences --- Psychology
Choose an application
Clinical health psychology --- Medicine and psychology --- Clinical health psychology. --- Medicine and psychology. --- Behavioral Medicine. --- Psychology, Clinical. --- behavioural medicine --- behavioural sciences --- health --- illness --- psychology --- psychosocial health --- Psychology --- Human medicine
Choose an application
Science --- Natural history --- Science. --- Natural history. --- Naturwissenschaften. --- Exacte wetenschappen. --- Colombia. --- Periodicals --- Life Sciences --- General and Others --- physical sciences --- natural sciences --- behavioural sciences --- chemical sciences --- mathematics --- biomedical sciences
Choose an application
Prisoners' families --- Children of prisoners --- Prisoners --- Family relationships --- Father and child --- Behavioural sciences --- Child custody --- Crime --- Criminal justice --- Criminal law --- Criminology --- Deviance (sociology) --- Justice --- Juvenile delinquency --- Law
Choose an application
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
Biomedicine. --- Pharmacology/Toxicology. --- Neurosciences. --- Receptors. --- Neurobiology. --- Behavioural Sciences. --- Pharmacy. --- Medicine. --- Toxicology. --- Animal behavior. --- Cell receptors. --- Médecine --- Neurosciences --- Toxicologie --- Pharmacie --- Animaux --- Récepteurs cellulaires --- Neurobiologie --- Moeurs et comportement --- Antipsychotic drugs. --- Schizophrenia --- Chemotherapy. --- Pathophysiology.
Choose an application
A Critical Companion to Zoosemiotics is the first attempt to systematize the discipline that studies animal communication and signification through its most important and/or problematic terms and concepts, and its most representative scholars. It is a companion, in that it attempts to cover the entire range of key words of the field, and it is critical, in that it aims not only to describe, but also to discuss and problematize such words. The book is conceived for zoosemiotic students, researchers and scholars as a valuable tool for consultation, reference, research and reflection, and it represents an ideal complement for reading and studying zoosemiotic books and essays.
Life Sciences. --- Behavioural Sciences. --- Forestry. --- Life sciences. --- Animal behavior. --- Forests and forestry. --- Sciences de la vie --- Animaux --- Forêts et sylviculture --- Moeurs et comportement --- Animal communication --- Human-animal relationships --- Semiotics --- Animal communication. --- Human-animal relationships. --- Semiotics.
Choose an application
humanities --- social sciences --- behavioural sciences --- Humanities --- Social sciences --- Social Sciences --- Humanities. --- Social sciences. --- Periodicals. --- Behavioral sciences --- Human sciences --- Sciences, Social --- Social science --- Social studies --- Civilization --- Learning and scholarship --- Classical education --- Science, Social --- Social Science --- Humanities.. --- Social Sciences.
Choose an application
The last iteration of the Canadian census (2008) that included questions regarding marriage and divorce reports that approximately 40% of marriages in that year will end in divorce before the 30th wedding anniversary. While only a proxy, the high divorce rate in Canada suggests a similarly high prevalence of relationship distress, a situation where one or both partners are dissatisfied with their intimate relationship and that is characterized by conflict. Relationship distress can result in higher levels of psychological and physical health concerns in both partners, in addition to health and social role impairments among children, other family members, co-workers and friends. Recent studies have helped to identify that the association between relationship distress and negative health outcomes is cyclical. Not only does relationship distress lead to negative psychological health outcomes such as depression, anxiety and substance abuse, it can also result from situations where couples must respond to and cope with these concerns. Other contributors to relationship distress are varied and can include such experiences as the diagnosis of a terminal illness, living with chronic disease, living with mental health disorders, infidelity, unresolved childhood trauma, among others. Couples therapy is widely practiced as a means to improve relationship distress, and is often an expected course of treatment when couples are faced with conflict. The main premise of is that guiding couples through their conflict as a collaborative team is more beneficial than working with only one member alone. While couples therapy is widely practiced, the effectiveness of couples therapy as an intervention to improve relationship distress is unclear. The purpose of this review is to summarize published research and evidence-based guidelines regarding the effectiveness of couples therapy for adults experiencing relationship distress from any cause.
Couples Therapy. --- Marriage --- Stress, Psychological --- psychology. --- therapy. --- Couples therapy. --- Adherence (medicine) --- Aggression --- Attachment theory --- Behaviour therapy --- Behavioural sciences --- Blinded experiment --- Clinical psychology --- Clinical significance --- Clinical trial --- Cognitive behavioral therapy
Choose an application
Post-traumatic stress disorder --- Treatment. --- Stress Disorders, Post-Traumatic --- Abnormal psychology --- Antidepressant --- Behavioural sciences --- Clinical medicine --- Clinical psychology --- Clinical trial --- Cognitive behavioral therapy --- Evidence-based medicine --- Eye movement desensitization and reprocessing --- Fluoxetine --- therapy.
Choose an application
Anxiety disorders. --- Yoga --- Post-traumatic stress disorder --- Anxiety disorders --- Depression, Mental --- Substance abuse --- Abnormal psychology --- Alcoholism --- Antidepressant --- Anxiety disorder --- Behavioural sciences --- Clinical medicine --- Clinical psychology --- Clinical trial --- Cognitive behavioral therapy --- Dysthymia --- Therapeutic use. --- Treatment.
Listing 1 - 10 of 45 | << page >> |
Sort by
|